Golden
Atomwise

Atomwise

Atomwise is a company that develops AI solutions for drug discovery.

Atomwise is an AI-based drug discovery company headquartered in San Francisco, California. Atomwise was founded in 2012 and was formerly known as Chematria.

In January 2019, Charles River Laboratories and Atomwise formed an alliance to provide integrated, AI-Driven drug discovery.

History and Approach

Atomwise’s technology was first developed by Dr. Wallach, a PhD student at the University of Toronto. The technology uses convolutional neural networks to predict the bioactivity of small molecules for drug discovery applications. It uses a statistical approach that extracts insights from experimental affinity measurements and protein structures to predict the binding of small molecules to proteins.

This tool allows chemists to pursue hit discovery, lead optimization and toxicity predictions. Atomwise analyzes billions of compounds to identify a small, specific subset for synthesis and testing.

AtomNet

AtomNet is Atomwise's deep convolutional network.

AtomNet represents a protein-ligand pair as a set of 3-dimensional volumetric pixels containing channels for carbon, oxygen, nitrogen, etc atom types. AtomNet applies local convolutional filters to structural target information to predict new active molecules for targets with no previously known modulators.

Timeline

People

Name
Role
Related Golden topics

Abraham Heifets

Founder

Alexander Levy

Founder

David E. Weekly

Investor

David Lee

Investor

Izhar Wallach

Founder

Jasna Delic

Employee

Jeff Chung

Investor

Jeff Huber

Investor

Mohammad Islam

Investor

Stefano Bernardi

Investor

Stephanie Rosenbloom

Employee

Further reading

Title
Author
Link
Type

Atomwise- News and Publications

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References